[CLS] O
BRCA1 O
is O
secreted O
and O
exhibits O
properties O
of O
a O
granin O
. O
[SEP] O

[CLS] O
The O
HRAS1 O
variable O
number O
of O
tandem O
repeats O
( O
VNTR O
) O
polymorphism O
, O
located O
1 O
kilobase O
( O
kb O
) O
downstream O
of O
the O
HRAS1 O
proto O
- O
oncogene O
( O
chromosome O
11p15 O
. O
5 O
) O
is O
one O
possible O
genetic O
modifier O
of O
cancer B
penetrance O
. O
[SEP] O

[CLS] O
3 O
. O
[SEP] O

[CLS] O
We O
have O
analyzed O
the O
27 O
exons O
and O
the O
promoter O
region O
of O
the O
RB1 O
gene O
in O
familial B
or I
sporadic I
bilateral I
retinoblastoma I
by O
using O
single O
- O
strand O
conformation O
polymorphism O
analysis O
. O
[SEP] O

[CLS] O
Subsequent O
molecular O
biology O
, O
biosynthetic O
, O
and O
immunofluorescence O
studies O
demonstrated O
that O
C2 O
secretion O
is O
impaired O
in O
Type B
II I
C2 I
deficiency I
because O
of O
different O
missense O
mutations O
at O
highly O
conserved O
residues O
in O
each O
of O
the O
C2Q0 O
alleles O
. O
[SEP] O

[CLS] O
Insect O
cells O
infected O
with O
recombinant O
baculovirus O
expressing O
normal O
vWF O
sequence O
secreted O
a O
disulfide O
linked O
dimeric O
molecule O
with O
an O
apparent O
molecular O
mass O
of O
150 O
kDa O
before O
reduction O
, O
yielding O
a O
single O
band O
of O
80 O
kDa O
after O
disulfide O
bond O
reduction O
. O
[SEP] O

[CLS] O
The O
WASP O
sequence O
contains O
two O
novel O
domains O
that O
are O
homologous O
to O
other O
proteins O
involved O
in O
action O
organization O
. O
. O
[SEP] O

[CLS] O
None O
of O
these O
patients O
had O
adrenocortical O
antibodies O
. O
[SEP] O

[CLS] O
Microcell O
hybrids O
containing O
only O
the O
region O
10pter O
- O
q11 O
were O
suppressed O
for O
tumorigenicity O
following O
injection O
of O
microcell O
hybrids O
into O
nude O
mice O
. O
[SEP] O

[CLS] O
Individuals O
who O
inherit O
one O
mutant O
allele O
are O
at O
increased O
risk O
for O
breast B
cancer I
, O
and O
the O
tumours B
they O
develop O
lose O
the O
wild O
- O
type O
allele O
by O
heterozygous O
deletion O
. O
[SEP] O

[CLS] O
Analysis O
of O
the O
intragenic O
polymorphism O
D17S855 O
supports O
common O
origins O
of O
the O
mutations O
. O
[SEP] O

[CLS] O
We O
have O
developed O
a O
multiplex O
heteroduplex O
analysis O
that O
is O
designed O
to O
analyze O
one O
- O
quarter O
of O
the O
coding O
sequence O
in O
a O
single O
- O
step O
screening O
procedure O
and O
that O
will O
detect O
approximately O
50 O
% O
of O
all O
BRCA1 O
mutations O
so O
far O
reported O
in O
breast B
/ I
ovarian I
cancer I
families O
. O
[SEP] O

[CLS] O
Previous O
investigations O
by O
Southern O
blot O
hybridization O
and O
PCR O
fragment O
- O
length O
analysis O
had O
revealed O
mutations O
in O
48 O
patients O
. O
[SEP] O

[CLS] O
No O
correlation O
between O
the O
location O
of O
frameshift O
or O
nonsense O
mutations O
and O
phenotypic O
features O
, O
including O
age O
at O
diagnosis O
, O
the O
number O
of O
tumor B
foci O
, O
and O
manifestation O
of O
nonocular B
tumors I
was O
observed O
. O
. O
[SEP] O

[CLS] O
Seven O
HD B
patients O
had O
36 O
repeats O
, O
which O
confirms O
that O
this O
allele O
is O
associated O
with O
disease O
. O
[SEP] O

[CLS] O
The O
A305E O
missense O
mutation O
accounted O
for O
48 O
% O
( O
24 O
/ O
50 O
) O
of O
mutant O
chromosomes O
in O
patients O
of O
western O
European O
descent O
, O
while O
the O
two O
predominant O
Jewish O
mutations O
each O
accounted O
for O
a O
single O
mutant O
chromosome O
. O
[SEP] O

[CLS] O
Variable O
levels O
of O
expression O
of O
Atm O
were O
observed O
in O
different O
tissues O
. O
[SEP] O

[CLS] O
Northern O
analysis O
of O
sf O
tissue O
samples O
indicated O
the O
presence O
of O
WASP O
mRNA O
in O
liver O
and O
skin O
, O
presumably O
as O
a O
consequence O
of O
lymphocytic O
infiltration O
, O
but O
non O
abnormalities O
in O
the O
amount O
or O
size O
of O
mRNA O
present O
. O
[SEP] O

[CLS] O
9 O
and O
8 O
. O
[SEP] O

[CLS] O
However O
, O
both O
models O
lack O
other O
frequent O
DM B
symptoms O
including O
the O
fibre O
- O
type O
dependent O
atrophy B
, O
myotonia B
, O
cataract B
and O
male B
- I
infertility I
. O
[SEP] O

[CLS] O
Mutations O
of O
the O
BRCA1 O
gone O
in O
humans O
are O
associated O
with O
predisposition O
to O
breast B
and I
ovarian I
cancers I
. O
[SEP] O

[CLS] O
Increased O
coronary B
heart I
disease I
in O
Japanese O
- O
American O
men O
with O
mutation O
in O
the O
cholesteryl O
ester O
transfer O
protein O
gene O
despite O
increased O
HDL O
levels O
. O
[SEP] O

[CLS] O
Increased O
CHD B
in O
men O
with O
mutations O
was O
primarily O
observed O
for O
HDL O
chol O
41 O
- O
60 O
mg O
/ O
dl O
; O
for O
HDL O
chol O
> O
60 O
mg O
/ O
dl O
men O
with O
and O
without O
mutations O
had O
low O
CHD B
prevalence O
. O
[SEP] O

[CLS] O
Mutation O
analysis O
in O
19 O
families O
of O
German O
, O
Swiss O
and O
Turkish O
descent O
by O
single O
- O
strand O
conformation O
polymorphism O
and O
sequencing O
resulted O
in O
the O
detection O
of O
seven O
novel O
and O
10 O
known O
mutations O
. O
[SEP] O

[CLS] O
When O
crossed O
onto O
the O
Small O
eye O
background O
, O
the O
transgene O
rescues O
the O
mutant O
phenotype O
. O
[SEP] O

